Does bio­phar­ma sup­port the Califf nom for FDA? Yeah, what­ev­er

!func­tion(e,i,n,s){var t=”In­fo­gramEm­beds”,d=e.getEle­ments­By­Tag­Name(“script”)[0];if(win­dow[t]&&win­dow[t].ini­tial­ized)win­dow[t].process&&win­dow[t].process();else if(!e.getEle­ment­ById(n)){var o=e.cre­ateEle­ment(“script”);o.async=1,o.id=n,o.src=”https://e.in­fo­gram.com/js/dist/em­bed-loader-min.js”,d.par­entN­ode.in­sert­Be­fore(o,d)}}(doc­u­ment,0,”in­fo­gram-async”);

Now that Pres­i­dent Joe Biden has drug his heels as long as pos­si­ble in se­lect­ing a new FDA com­mis­sion­er, we’re set to wel­come the new boss — same as the old boss.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE